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Abstract
Background: Interferon gamma release assays, including the QuantiFERON® TB Gold In Tube
(QFT) have been shown to be accurate in diagnosing Mycobacterium tuberculosis infection. These
assays however, do not discriminate between latent TB infection (LTBI) and active TB disease.
Methods: We recruited twenty-three pulmonary TB patients and 34 household contacts from
Cape Town, South Africa and performed the QFT test. To investigate the ability of new host
markers to differentiate between LTBI and active TB, levels of 29 biomarkers in QFT supernatants
were evaluated using a Luminex multiplex cytokine assay.
Results: Eight out of 29 biomarkers distinguished active TB from LTBI in a pilot study. Baseline
levels of epidermal growth factor (EGF) soluble CD40 ligand (sCD40L), antigen stimulated levels
of EGF, and the background corrected antigen stimulated levels of EGF and macrophage
inflammatory protein (MIP)-1β were the most informative single markers for differentiation
between TB disease and LTBI, with AUCs of 0.88, 0.84, 0.87, 0.90 and 0.79 respectively. The
combination of EGF and MIP-1β predicted 96% of active TB cases and 92% of LTBIs. Combinations
between EGF, sCD40L, VEGF, TGF-α and IL-1α also showed potential to differentiate between TB
infection states. EGF, VEGF, TGF-α and sCD40L levels were higher in TB patients.
Conclusion: These preliminary data suggest that active TB may be accurately differentiated from
LTBI utilizing adaptations of the commercial QFT test that includes measurement of EGF, sCD40L,
MIP-1β, VEGF, TGF-α or IL-1α in supernatants from QFT assays. This approach holds promise for
development as a rapid diagnostic test for active TB.
Background
Commercial  in vitro T-cell interferon gamma (IFN-γ)
release assays (IGRAs) including the QuantiFERON® tests
(Cellestis, Victoria, Australia) and T SPOT. TB  (Oxford
Immunotec, Abington, UK) have been introduced into
clinical practice for the diagnosis of Mycobacterium tubercu-
losis (M. tb) infection. These assays make use of M. tb spe-
cific antigens, ESAT-6 and CFP-10, and a third antigen,
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TB7.7 (Rv2654) in the QuantiFERON® TB Gold In-Tube
(QFT).
The IGRAs (reviewed in [1]) employ whole blood or
peripheral blood mono nuclear cells, which are cultured
overnight with the TB specific antigens. M. tb infected
individuals harbour pre-activated T-cells which rapidly
respond by the release of cytokines including IFN-γ when
challenged with M. tb antigens. The IFN-γ released by
these activated cells is then quantitated by ELISA in the
QuantiFERON assays or by enumeration of spot-forming
cells in the ELISPOT-based T SPOT. TB [1].
IGRAs have been extensively studied, and shown to be
very sensitive and specific for latent M. tb infection (LTBI)
especially in comparison to the tuberculin skin test (TST)
[2-5]. The many other advantages offered by these assays
over the TST have been well documented [1,3,6].
The current standard tests for active tuberculosis (TB) have
serious limitations. Sputum smear examination for acid-
fast bacilli (AFB) has a low sensitivity and cannot discrim-
inate between M. tb and non tuberculous mycobacteria,
and sputum culture for M. tb takes several days to weeks
to yield a result [7]. Diagnosing TB in sputum smear and
culture-negative patients and in those with extra-pulmo-
nary disease remains challenging [8]. While IGRAs are
useful in the diagnosis of M. tb infection, an important
limitation of these assays is their inability to discriminate
between LTBI and active TB. These assays are therefore of
little value in high TB incidence areas with a very high
LTBI burden. Discovery of biomarkers that can rapidly dif-
ferentiate between the two infection states would be a
major breakthrough.
Recent technological advances have made it possible to
screen for many biomarkers in as little as 25 μl of sample
using Luminex multiplex cytokine beaded arrays. We
hypothesized that M. tb specific antigenic stimulation of
whole blood would result in the production of multiple
biomarkers, some of which would be unique to either
LTBI or active TB disease. In the present study, levels of 29
markers are measured in QFT supernatants and promising
analytes are identified with ability to discriminate
between LTBI and active TB.
Methods
Study subjects
We sequentially recruited 23 pulmonary TB patients and
34 household contacts (HHC) of pulmonary TB patients
from the Ravensmead/Uitsig community in the Western
Cape Province of South Africa between October 2006 and
April 2007. The TB incidence in South Africa was 940 per
100,000 while the case notification rate was 628 per
100,000 in 2006[9]. BCG vaccination (Danish strain,
1331, Statens Serum Institute, Copenhagen, Denmark) is
routinely administered at birth in the study area. All the
pulmonary TB patients were self-reporting, untreated
cases with a first episode of TB and were all AFB positive
on two smears. HHCs had been living in the same house
as an adult TB case who was diagnosed not more than 2
months before recruitment of the contact. All HHCs had
normal chest X-rays and AFB negative assisted sputum
samples. Inclusion criteria for all participants were: age 10
to 60 years, negative HIV test (Abbot Determine™ HIV 1/
2; Abbott, Wiesbaden, Germany), willingness to give writ-
ten informed consent for participation and availability for
TST reading at 48–72 hours (HHCs only). Exclusion crite-
ria for participants included previous or current TB treat-
ment, serious concomitant chronic conditions, steroid
therapy within the past 6 months and pregnancy. Demo-
graphic data was collected and a clinical questionnaire
completed. Ethical approval for the study was obtained
from the Committee for Human Research of the Univer-
sity of Stellenbosch.
Diagnostic tests
At enrolment, 10 ml of heparinized blood was collected
from all participants and transported (at ambient condi-
tions) within 2 hours of collection to the laboratory. The
QFT test (using 3 ml of blood) was performed on all study
subjects and interpreted for TB infection according to the
manufacturer's instructions [10] (see details below). The
TST, using 2 TU PPD (Mantoux PPD, Statens Serum Insti-
tute), was performed on all HHC after blood collection.
IFN-γ measurement and initial screening for biomarkers
IFN-γ measurement in QFT supernatants was done with
the QFT ELISA [10]. Tests were regarded as positive for TB
infection if the difference between the TB antigen (stimu-
lated) and the unstimulated supernatant was = 0.35 IU/ml
regardless of mitogen value. The tests were judged as neg-
ative when this difference was < 0.35 IU/ml, provided that
the value of mitogen stimulated supernatant was ≥ 0.5 IU/
ml after subtraction of the unstimulated value. These
results were generated using the QFT analysis software,
version 2.50.
To reduce cost we initially performed 29-plex Luminex
assays on a subset of randomly selected supernatants from
10 TB cases and 9 HHCs with positive QFT results. We
only included QFT positive individuals in the pilot study
because our objective was to identify markers that could
discriminate between LTBI and active TB. Levels of inter-
leukin (IL)-1α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-10, IL-
12(p40), IL-12(p70), IL-13, IL-15, IL-17, IL-8 (CXCL8)
interleukin 1 receptor antagonist (IL-1ra), soluble CD40
ligand (sCD40L), epidermal growth factor, (EGF), eotaxin
(CCL11), fractalkine, granulocyte colony stimulating fac-
tor (G-CSF), granulocyte monocyte stimulating factorBMC Pulmonary Medicine 2009, 9:21 http://www.biomedcentral.com/1471-2466/9/21
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(GM-CSF), interferon gamma (IFN-γ), interferon induci-
ble protein 10 (IP-10 or CXCL10), monocyte chemotactic
protein-1 (MCP-1 or CCL2), macrophage inflammatory
protein (MIP)-1α or CCL3, MIP-1β (CCL4), transforming
growth factor (TGF)-α, tumour necrosis factor (TNF)-α
and vascular endothelial growth factor (VEGF) were eval-
uated in unstimulated (cytokineNil), M. tb specific antigen
(cytokineAg) and phytohaemagglutinin (mitogen) stimu-
lated QFT supernatants.
We used the unstimulated (Nil), M. tb antigen stimulated
(Ag) and mitogen stimulated supernatant data, as well as
the difference between the antigen stimulated (Ag-Nil) or
the mitogen stimulated (Mit-Nil) and the unstimulated
supernatant levels as separate variables in analysis of the
data. This was done to allow evaluation of baseline
marker levels, M. tb antigen or mitogen stimulated levels
and differences between these levels in differentiating
between TB infection states.
The performance of single and sets of biomarkers in differ-
entiating between active TB and absence of active TB was
evaluated in a) QFT positive samples, and b) all samples
regardless of QFT result.
Eight out of 29 biomarkers that showed significant differ-
ences or trends for differences between LTBI and active TB
after evaluation on the 19 QFT positive subjects were
selected and evaluated on the rest of the participants (n =
38) with a customized 8-plex kit. The 8 markers were IL-
1α, sCD40L, EGF, IFN-γ, MIP-1β, TGF-α, TNF-α and
VEGF. The data collected on these 8 analytes from the 19
participants tested with the 29-plex kit was combined
with the data collected on the remaining 38 participants
tested with the customized 8-plex kit for the final analysis.
Luminex assay
Biomarker levels were measured using LINCO-plex® kits
(Millipore, St. Charles, Missouri, USA) on the Bio Plex
platform (Bio Plex™, Bio Rad Laboratories) according to
the Linco instructions [11]. All supernatants were diluted
1:1 with the kit serum matrix diluent, following optimiza-
tion experiments. Only the unstimulated and M. tb anti-
gen stimulated supernatants were used in the customized
8-pex kits as the levels of markers in the mitogen stimu-
lated supernatants evaluated with the 29-plex were not
useful in the models for differentiating between LTBI and
active TB. All samples were evaluated in duplicate by a sin-
gle technician who was blinded to participant groups. All
analyte levels in the quality control reagents included in
the kits were within the expected ranges. To access the var-
iability in sample runs, a supernatant from a single QFT
positive household contact (R386) was evaluated on all
plates. Both the intra-plate and inter-plate coefficients of
variation for duplicate runs of this sample varied between
analytes, but were mostly below 20% (range, 9.5% –
41.3%). The standard curve for all biomarkers ranged
from 3.2–10000 pg/ml. Bio-Plex Manager Software, ver-
sion 4.1.1 was used for the analysis of the data.
Statistical analysis
IFN-γ levels measured by the QFT ELISA (IU/ml) were
converted to pg/ml by multiplying by a factor of 40 [12].
All analyte levels obtained with the Luminex assay were
multiplied by 2 to correct for the dilution. Differences
between study groups were determined using the Mann-
Whitney U test. Cut-off levels for differentiating between
groups were determined by receiver operator characteris-
tic (ROC) curve analysis using the "R" statistical program-
ming language. General discriminant analysis (GDA) and
support vector machine (SVM) models (described in [13])
were used to evaluate the predictive abilities of combina-
tions of biomarkers for differentiating between M. tb
infection states. Optimal combinations of biomarkers
were investigated by performing best subsets analysis in
both cases (GDA and SVM). Prediction accuracy were esti-
mated using leave-one-out cross validation. This method
was used due to the small sample size. A 5% significance
level was used as guideline for determining significant
associations. The data was analysed using the Statistica 8
software, Statsoft (Ohio, USA).
Results
QFT testing
All the household contacts with a positive QFT test
(73.5%) also had a positive TST (10 mm cut-off). Only 10
out of the 57 participants evaluated in the study had neg-
ative QFT tests and no indeterminate results were
observed. The demographic and clinical information col-
lected on the participants is shown in table 1.
Analysis of QFT supernatants with the 29-plex kit and 
selection of promising markers for customized 8-plex kit
M. tb antigen stimulation of whole blood resulted in the
production of significantly higher levels of sCD40L and
VEGF in latently infected individuals compared to active
TB patients. There were also significant differences in the
unstimulated levels of EGF, TGF-α, TNF-α and sCD40L
between LTBI and active TB (Table 2). IL-1α, MIP-1β and
IFN-γ showed borderline differences between the two
groups and were included in the customized 8-plex kit. An
excellent correlation was observed between the ELISA and
Luminex measured IFN-γ levels (both with the 29- and 8-
plex assays), although the levels measured by ELISA were
often higher than those detected by the Luminex assay (r
= 0.88; p < 0.0001).
Ability of eight selected markers to diagnose active TB
a) Discrimination between LTBI and TB disease in QFT positive 
supernatants
Unstimulated (Nil), TB antigen stimulated (Ag) and antigen
stimulated minus unstimulated (Ag-Nil) levels of EGF,BMC Pulmonary Medicine 2009, 9:21 http://www.biomedcentral.com/1471-2466/9/21
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sCD40L, and TGF-αAg, MIP-1βAg-Nil and VEGFNil were the
most accurate single markers that differentiated between
the two infection states. The median levels of the individ-
ual markers in the two groups, cut-off values and their
respective accuracies (sensitivity and specificity) in distin-
guishing QFT positive pulmonary TB cases from QFT pos-
itive HHCs are shown in table 3 while ROC curves are
shown in figure 1.
Fitting two mathematical models (general discriminant
analysis [GDA] and support vector machines [SVM]) to
the data indicated that optimal prediction of TB infection
states could be achieved with combinations of 3 variables.
EGFNil was the most frequently occurring marker in both
the GDA and SVM biomarker combinations differentiat-
ing between the QFT positive pulmonary TB cases and the
QFT positive HHCs (figure 2). A combination of EGFNil,
MIP-1βAg-Nil and IL-1αNil (or IL-1αAg) classified pulmo-
nary TB cases with an accuracy of 95.5% in a resubstitu-
tion classification matrix and with 90.9% after leave-one-
out cross validation. The same biomarker combination
classified the QFT positive HHCs with an accuracy of
88.8% after leave-one-out cross validation. Other three-
variable combinations including any two of EGFNil, EGFAg
or EGFAg-Nil plus a third marker selected from VEGFNil,
VEGFAg, TGF-αAg-Nil or MIP-1βNil in GDA, classified the
Table 1: Clinical and demographic characteristics of study subjects.
All Pulmonary TB Household contacts
Number of participants 57 23 34
Age, mean yr ± SD 31.2 ± 13.9 30.3 ± 13.6 31.8 ± 14.2
Age range, yr 10.1 – 59.9 10.1 – 57.4 10.7 – 59.9
Male/female ratio 31/26 17/6 14/20
TST mean, mm na nd 22.8
TST range, mm na na 0.0–46.0
TST pos*, % na na 87.5
QFT pos, % 82.5 95.6 73.5
QFT = QuantiFERON TB Gold In Tube, TB = active tuberculosis, TST = tuberculin skin test, yr = years, SD = standard deviation, na = not 
applicable, nd = not done, * = Two household contacts did not return for TST reading.
Table 2: Median levels of promising analytes as measured with the 29-plex assay
Analyte All subjects
(n = 19)
Active TB cases
(n = 10)
LTBI
(n = 9)
p-value
(Active TB vs LTBI)
EGFNil 73.0
(23.4–148.9)
106.2
(40.8–148.9
51.4
(23.4–141.3
0.02
IFN-γAg-Nil 99.1
(0.0–1265.0)
57.0
(0.0–646.3)
127.6
(38.6–1265.5)
0.08
IP-10* Ag-Nil 18139.0
(5313.0–>20000.0)
14446.0
(5313.0–>20000.0)
18224.0
(12470.0–>20000.0)
0.27
IL-2*Ag-Nil 160.0
(10.2–1778.0)
106.6
(10.2–640.9)
164.0
(57.8–1778.0)
0.19
IL-1αAg-Nil 76.6
(0.0–235.4)
118.0
(0.0–235.4)
23.3
(0.0–158.5)
0.04
MIP-1βAg-Nil 1770
(0.0–7847.0)
1210.0
(0.0–4098.0)
3220
(960.8–7847.0)
0.06
TNF-αNil 50.8
(7.3–633.7)
94.9
(19.8–633.7)
15.9
(7.3–293.6)
0.01
TGF-αNil 13.3
(0.0–230.1)
28.5
(0.0–230.1)
6.2
(0.0–13.3)
<0.01
VEGFAg-Nil 0.0
(0.0–77.3)
0.0
(0.0–31.8)
36.3
(0.0–77.3)
<0.01
sCD40LNil 869.0
(245.2–9852.0)
1388.0
(455.4–4038.0)
599.4
(245.2–9852.0)
0.03
sCD40LAg-Nil 0.0
(0.0–9944.0)
0.0
(0.0–4.6)
309.4
(12.2–9944.0)
<0.01
Median levels (pg/ml) and ranges (in parenthesis) of analytes with significant or near significant differences between TB cases and the latently 
infected individuals obtained with the 29-plex assay. * Marker was not included in the customized 8-plex kit. Levels shown as >20000 pg/ml were 
above the highest point on the standard curve.BMC Pulmonary Medicine 2009, 9:21 http://www.biomedcentral.com/1471-2466/9/21
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QFT positive TB cases with accuracies above 90.0% in
resubstitution classification matrix (range, 90.9–95.5%)
and above 86.0% (range, 86.4–90.9%) after leave-one-
out cross validation. The same combinations of analytes
accurately classified more than 88.0% of HHC (range,
88.8–96.0%) in resubstitution classification matrix and
up to 88.0% (range, 84.0–88.0%) after leave-one-out
cross validation.
In SVM analysis, two three-marker combinations (EGFNil/
EGFAg-Nil/MIP-1βAg-Nil  and EGFNil/IL-1αNil/MIP-1βAg-Nil)
differentiated QFT positive TB cases from QFT positive
HHCs with overall accuracies of 86.0% and 90.4% respec-
tively, and above 85.0% after leave-one-out cross valida-
tion. The predictive abilities of the top 6 and 9 three-
marker combinations in GDA and SVM models, for differ-
entiating between positive QFT results as active TB or
LTBI, are shown on additional files 1 and 2 respectively.
b)i. Differentiating between TB cases and household contacts 
irrespective of QFT results
EGFNil/Ag-Nil, sCD40LNil/Ag/Ag-Nil, MIP-1βAg-Nil and TGF-αAg
were the most accurate single markers that differentiated
between pulmonary TB cases and HHCs irrespective of
QFT results (figures 3 and 4).
EGFAg-Nil was the most frequently occurring marker in the
top three-analyte GDA model combinations that most
accurately differentiated cases from contacts irrespective
of QFT results, while EGFNil and EGFAg-Nil were the most
frequent in the top SVM model combinations (figure 5).
Three-marker models comprising i) EGFNil, EGFAg  or
EGFAg-Nil, or ii) any two of the EGF conditions plus any
one of IL-1αNil, IL-1αAg or MIP-1βAg-Nil, or iii) any one of
the EGF conditions plus any two of IL-1αNil, IL-1αAg or
MIP-1βAg-Nil differentiated between TB cases and HHCs in
GDA with accuracies up to 96.0% (range, 87.0–96.0%)
for TB cases and up to 94.1% (range, 85.3–94.1%) for
HHCs. In leave-one-out cross validation the accuracies of
the biomarker combinations were between 82.6% and
87.0% in TB cases and 85.3% and 91.2% in HHCs.
The top two marker combinations in SVM analysis were
EGFNil/EGFAg-Nil/MIP-1βAg-Nil  and EGFNil/EGFAg-Nil/IL-
1αAg. Both marker combinations correctly classified
87.0% of TB patients and 91.2% of HHCs respectively,
with an overall accuracy of 85.3%. The most accurate GDA
and SVM model combinations for discriminating between
TB cases and HHCs are shown on additional files 3 and 4
respectively.
b) ii. Differentiating between QFT positive and QFT negative 
household contacts
We stratified the household contacts according to QFT sta-
tus and evaluated whether there were any differences in
biomarker levels between them. Of the 8 markers
included in the customized kit, only IFN-γ was signifi-
Table 3: Abilities of top individual analytes to discriminate positive QFT results as active TB or LTBI
Marker Level in Pulmonary TB
(n = 22)
Level in LTBI
(n = 25)
Cut-off
(pg/ml)
Sensitivity
%
Specificity
%
PPV,
%
NPV,
%
EGFNil 115.5
(39.1–222.2)
34.5
(15.2–214.0)
76.16 90.9 84.0 83.3 91.3
EGFAg 65.7
(23.4–121.8)
27.2
(12.2–487.9)
46.68 81.8 88.0 85.7 84.6
EGFAg-Nil -44.9
(-116.1–0.44)
-7.0
(-48.9–274.0)
-25.6 92.0 81.8 85.1 90.0
TGF-αAg 22.2
(1.0–168.0)
13.4
(4.3–47.1)
13.78 81.8 60.0 64.3 78.9
IFN-γAg-Nil 99.3
(-216.4–699.8)
206.9
(8.7–6112.0)
106.68 80.0 54.5 66.7 70.6
sCD40LNil 3995.0
(876.1–10245.0)
1002.0
(220.4–>20000)
2307.54 86.4 80.0 79.2 87.0
sCD40LAg 1974.0
(883.0–13493.0)
1040.0
(383.2–>20000)
1563.66 86.4 72.0 73.1 85.7
sCD40LAg-Nil -1502.0
(-5339.0–3496.0)
10.6
(-3527.0–3927.0)
-471.06 88.0 68.2 75.9 83.3
MIP-1βAg-Nil 458.5
(-1035–2321.0)
1833.0
(290.0–6890.0)
836.18 84.0 63.6 72.4 77.8
VEGFNil 83.4
(0.0–482.3)
19.5
(0.0–415.8)
72.78 63.6 84.0 77.8 72.4
Median levels (pg/ml) and ranges (in parenthesis) of individual markers measured in QFT positive supernatants and abilities to discriminate between 
positive QFT results as either pulmonary TB or LTBI. Only markers with either sensitivity and/or specificity ≥ 80.0% between groups are shown. 
LTBI = household contacts with both positive QFT and TST results, PPV = positive predictive value, NPV = negative predictive. Levels shown as 
>20000 pg/ml were above the range of the standard curve.BMC Pulmonary Medicine 2009, 9:21 http://www.biomedcentral.com/1471-2466/9/21
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cantly different between the two groups (TB antigen stim-
ulated levels, p = < 0.001, corrected for background [IFN-
γ Ag-Nil], p = < 001).
Discussion
The ability to diagnose TB infection, and distinguish
active TB from LTBI by measurement of a limited number
of analytes on a small amount of blood in an overnight
assay would be a major advance over the currently availa-
ble TB diagnostic tests. In this study, we have shown for
the first time that multiple biomarkers measured in QFT
test supernatants have high ability to discriminate
between active TB and the absence of active disease. This
has significant implications for the diagnostic utility of
the QFT test. The top single markers were EGF and
sCD40L. Three-marker combinations of EGF with MIP-
1β, sCD40L, IL-1α or VEGF showed promising results
with the top model comprising EGFNil, EGFAg-Nil and MIP-
1βAg-Nil.
The ability of these markers to differentiate between dif-
ferent M. tb infection states is probably a reflection of suc-
Receiver operator characteristics curves showing the accuracies of top individual analytes in discriminating between active TB  and latent TB infection Figure 1
Receiver operator characteristics curves showing the accuracies of top individual analytes in discriminating 
between active TB and latent TB infection. Receiver operator characteristic (ROC) curves for the accuracies of single 
analytes to differentiate between active TB and LTBI in QFT positive individuals. Only ROC curves for markers that differenti-
ated between the two infection states with AUCs ≥ 0.73 are shown. AUC = Area under the curve.
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cessful and unsuccessful immunological responses
against the pathogen. The successful control of M. tb infec-
tion by the host immune response is largely dependent on
T-cells, macrophages and a balance between pro-inflam-
matory and regulatory cytokines and chemokines. Pulmo-
nary TB granulomas, including areas of caseous necrosis,
are rich in growth factors such as EGF, TGF-α and VEGF
and provide good growth environments for mycobacteria,
including  M. tb [14,15]. In addition to enhancing the
growth of mycobacteria within granulomas, Bermudez
and co-workers [14] showed that both M. tb and M. avium
express receptors for EGF. VEGF, an angiogenesis media-
tor, has been associated with disease activity in both pleu-
ral TB and TB meningitis [16,17] and levels decline after
successful TB treatment [18]. Both the unstimulated and
TB antigen stimulated levels of these growth factors were
higher in TB patients than in LTBI in this study.
MIP-1β and IL-1 are produced by macrophages. MIP-1β is
known to modulate macrophage functions, is an impor-
tant mediator of chronic inflammatory processes [19,20],
and is a potent macrophage, lymphocyte and specifically
activated CD4+ lymphocyte chemo-attractant [20]. IL-1
favours a TH1 immune response [21] and has been shown
to play an important role in the formation of granulomas
[22] along with TNF-α. Although the Mann-Whitney U
test showed no significant differences between the
unstimulated levels of MIP-1β, and both the unstimulated
and M. tb antigen stimulated levels of IL-1α in the differ-
ent TB infection states, multivariate analysis showed that
lower levels of both markers were characteristic of active
disease.
CD40L, is a costimulatory molecule that is expressed on
activated CD4+ T cells and is involved in their activation
and development of effector functions [23]. Mizusawa
and co-workers [24] reported significantly higher plasma
levels of sCD40L in patients with cavitary TB lesions, com-
pared to those without such lesions. The median levels of
sCD40L were higher in TB patients in the present study.
While there was no significant difference in the median
unstimulated and the antigen stimulated levels in the
non-diseased group, unstimulated levels were higher than
the antigen stimulated levels in TB patients. Because
patients in this study were not classified according to the
extent of disease on X-ray, future studies will have to
investigate the effect of disease severity on test perform-
ance.
Indeterminate results have been an issue of concern, and
are often reported in IGRA studies. They frequently occur
in immonocompromised subjects [25,26] and have also
been observed in children under the age of 5 years [26].
Previous reports have highlighted the potential roles of IP-
10, IL-2 and MCP-2 alongside IFN-γ in diagnosing M. tb
infection [27-29]. These studies revealed that combining
IFN-γ and IP-10 measurement in QFT supernatants
enhances the sensitivity for diagnosing M. tb infection and
decreases the proportion of indeterminate results [27,28].
We also observed very high levels of IP-10 in our 29-plex
Frequency of individual analytes in top models for discriminating between active TB and latent TB Figure 2
Frequency of individual analytes in top models for discriminating between active TB and latent TB. The columns 
represent the number of inclusions of individual markers into the most accurate three-analyte models by general discriminant 
and support vector machine analysis (6 and 10 models, respectively) for discriminating between active pulmonary TB cases and 
LTBI in participants with positive QFT results.
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measurements, and which correlated with IFN-γ levels (r
= 0.51, p = 0.009) but like IFN-γ, IP-10, which helps to
amplify IFN-γ responses by its effects on macrophages,
does not differentiate between active TB and LTBI. IFN-γ
or IP-10 detection could be used in a first step of a test
based on M. tb antigen stimulated whole blood culture to
diagnose (M. tb) infection. A second step of the test could
be performed if positive IFN-γ/IP-10 results are obtained
to measure three-marker combinations of EGF, sCD40L,
MIP-1β, VEGF, IL-1α or TGF-α levels by ELISA or multi-
plex cytokine assays, to differentiate individuals with
active TB from LTBI. Future larger studies should evaluate
both QFT positive and negative participants to ascertain
whether a one-step three-marker test is sufficient to diag-
nose active TB or whether a two-step strategy consisting of
a conventional QFT test followed by a three-marker assay
in those with a positive QFT result yields the best results.
Either approach may allow diagnosis of TB disease with
high accuracy within 24 hours after presentation of a
patient at the health care service, with only 3 ml of blood
Receiver operator characteristics curves showing the accuracies of top individual analytes in discriminating between TB disease  and the absence of active TB irrespective of QFT results Figure 3
Receiver operator characteristics curves showing the accuracies of top individual analytes in discriminating 
between TB disease and the absence of active TB irrespective of QFT results. Only ROC curves for markers that 
differentiated between groups with AUCs ≥ 0.73 are shown. AUC = Area under the curve.
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and without the requirement of a second visit by the
patient.
The levels of some of the markers investigated in this
study (EGF, sCD40L and VEGF) were lower in the TB anti-
gen stimulated than in the unstimulated QFT tubes. The
reasons for this difference might relate to the expression
kinetics of the different markers after stimulation with the
TB antigens. Another explanation could be that markers
are consumed due to possible co-expression of soluble or
membrane bound receptors after stimulation. The actual
mechanism behind this observation is beyond the scope
of this small study and may need to be investigated further
in future studies. It has been suggested that some
heparinized blood collection tubes may contain endo-
toxin, which may induce cytokine production during sub-
sequent culture. In the present study blood samples were
collected in heparinized tubes prior to transfer to the QFT
tubes whereas the manufacturers recommend collection
directly in the QFT tubes which are endotoxin free. Possi-
ble endotoxin contamination, however, would not
explain the higher levels of some analytes in unstimulated
than in stimulated samples as the blood from each partic-
ipant would be collected in a single heparinized tube and
both samples would be exposed to the same level of con-
taminants. Furthermore, as the levels in unstimulated
samples were generally not very high, it is unlikely that
endotoxin could have obscured significant analyte pro-
Levels of individual analytes in all TB cases (TB) and household contacts (HHC) Figure 4
Levels of individual analytes in all TB cases (TB) and household contacts (HHC). Each dot represents the analyte 
level of one participant in the study and horizontal lines represent the median values. Asterixes indicate significant differences 
between the TB cases (n = 23) and household contacts (n = 34). ##: p < 0.0001, #: p < 0.01, ¶¶: p = 0.01, ¶: p = 0.02. Nil: 
unstimulated analyte levels, Ag: Levels obtained after stimulation with Mycobacterium tuberculosis specific antigen cocktail 
(ESAT-6, CFP-10 and TB7.7), Ag-Nil: difference between the Mycobacterium tuberculosis specific antigen stimulated and the 
unstimulated levels.
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duction in antigen stimulated samples. We have previ-
ously also observed the same pattern of higher
unstimulated than stimulated analyte levels in samples
that were collected directly into QFT tubes (unpublished
data). Future studies should employ collection directly
into QFT tubes.
The main limitation of our study is the relatively small
number of study participants and the cross – sectional
design. Longitudinal cohort studies will be required with
careful clinical characterization of participants into TB
infection and disease groups to validate the accuracies and
the cut-off values of the markers identified in this study.
This will require a prospective study whereby misclassifi-
cation of active and latent TB by these cytokine combina-
tions is noted. Future studies should also access the utility
of the three-marker tests in smear negative TB, extrapul-
monary TB, immune compromised subjects (especially
HIV infected patients), children and people with other
lung infections like acute bacterial pneumonia. Addi-
tional biomarkers should also be evaluated as new multi-
plex assays become available. Additionally, development
of suitable point-of-care tests will be needed, using easy-
to-use, readily accessible and less costly techniques like
ELISA assays (as opposed to Luminex).
Conclusion
In conclusion, our preliminary results suggest that active
TB may be accurately identified within 24 hours utilizing
an adaptation of the commercial QFT assay where detec-
tion of a combination of three host markers (selected
from EGF, sCD40L, MIP-1β, VEGF, TGF-α or IL-1α) is per-
formed on QFT supernatants. The results hold promise for
the development of a rapid and sensitive test for active TB.
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Frequency of individual analytes in models for discriminating between active TB and no active TB Figure 5
Frequency of individual analytes in models for discriminating between active TB and no active TB. The columns 
represent the number of inclusions of individual markers into the most accurate three-analyte models by general discriminant 
and support vector machine analysis (6 and 10 models, respectively) in discriminating between active pulmonary TB cases and 
participants without active TB irrespective of QFT results.
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